Home » Stocks » HBIO

Harvard Bioscience, Inc. (HBIO)

Stock Price: $3.30 USD 0.09 (2.80%)
Updated Oct 29, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 128.51M
Revenue (ttm) 105.47M
Net Income (ttm) -8.17M
Shares Out 38.94M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE 27.25
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 29, 2020
Last Price $3.30
Previous Close $3.21
Change ($) 0.09
Change (%) 2.80%
Day's Open 3.19
Day's Range 3.15 - 3.31
Day's Volume 116,417
52-Week Range 1.39 - 4.41

More Stats

Market Cap 128.51M
Enterprise Value 179.75M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 38.94M
Float 34.37M
EPS (basic) -0.21
EPS (diluted) -0.21
FCF / Share 0.24
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 7.24%
Payout Ratio n/a
Shares Short 1.36M
Short Ratio 11.63
Short % of Float 3.95%
Beta 1.52
PE Ratio n/a
Forward PE 27.25
P/FCF Ratio 13.81
PS Ratio 1.22
PB Ratio 1.54
Revenue 105.47M
Operating Income -2.45M
Net Income -8.17M
Free Cash Flow 9.31M
Net Cash -51.24M
Net Cash / Share -1.32
Gross Margin 61.21%
Operating Margin -2.32%
Profit Margin -7.70%
FCF Margin 8.82%
ROA -0.67%
ROE -10.44%
ROIC -2.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.50*
(36.36% upside)
Low
4.00
Current: $3.30
High
5.00
Target: 4.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue11612177.41105109109105111109108
Revenue Growth-3.81%56.02%-25.94%-3.81%0%3.32%-5.4%2.12%0.63%-
Gross Profit64.3263.1839.1748.4248.7249.3447.7052.3450.1951.81
Operating Income0.380.98-0.64-3.00-1.716.621.547.838.4110.22
Net Income-4.69-2.92-0.87-4.31-19.042.36-1.832.373.8119.02
Shares Outstanding37.8136.4534.7534.2133.5932.1730.3828.8028.4528.97
Earnings Per Share-0.12-0.08-0.02-0.13-0.570.07-0.060.080.130.65
EPS Growth--------38.46%-80%-
Operating Cash Flow8.052.881.065.380.714.354.068.066.6512.29
Capital Expenditures-1.22-0.99-0.88-1.45-2.95-0.86-1.56-1.74-1.48-0.81
Free Cash Flow6.831.900.183.94-2.253.492.506.335.1711.48
Cash & Equivalents8.348.175.195.606.7414.1325.7720.6817.9219.70
Total Debt64.4760.8011.7513.7518.7321.4524.7512.9516.3018.01
Net Cash / Debt-56.13-52.62-6.56-8.15-11.99-7.321.027.731.621.70
Assets165169109108120136135133127125
Liabilities83.1885.8928.4535.5742.4540.4540.9829.2731.1434.55
Book Value81.6982.7280.9072.2077.6095.4794.4910495.5090.25
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Harvard Bioscience, Inc.
Country United States
Employees 505
CEO James W. Green

Stock Information

Ticker Symbol HBIO
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: HBIO
IPO Date December 7, 2000

Description

Harvard Bioscience develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, and BTX brands. It also develops and manufactures data acquisition systems for use with custom amplifier configurations under; vivo-systems solution for in vivo recordings with microelectrode arrays; and vitro-systems for extracellular recordings from microelectrode arrays in vitro. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions under the DSI and Buxco brands. It markets its products through sales organizations, websites, catalogs, and distributors to research scientists at pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories. Harvard Bioscience, Inc. was founded in 1901 and is headquartered in Holliston, Massachusetts.